A randomized feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer

Forskningsoutput: Tidskriftsbidrag › Publicerat konferensabstract

Standard

A randomized feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer. / Margolin, S; Carlsson, L; Hellström, M; Karlsson, P; Lidbrink, E; Linderholm, B; Lindman, H; Malmström, Per; Sköld Pettersson, D; Bergh, J.

I: European Journal of Cancer Supplements, Vol. 6, Nr. 7, 2008, s. 116-117.

Forskningsoutput: Tidskriftsbidrag › Publicerat konferensabstract

Harvard

Margolin, S, Carlsson, L, Hellström, M, Karlsson, P, Lidbrink, E, Linderholm, B, Lindman, H, Malmström, P, Sköld Pettersson, D & Bergh, J 2008, 'A randomized feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer', European Journal of Cancer Supplements, vol. 6, nr. 7, s. 116-117. https://doi.org/10.1016/S1359-6349(08)70548-2

APA

Margolin, S., Carlsson, L., Hellström, M., Karlsson, P., Lidbrink, E., Linderholm, B., Lindman, H., Malmström, P., Sköld Pettersson, D., & Bergh, J. (2008). A randomized feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer. European Journal of Cancer Supplements, 6(7), 116-117. https://doi.org/10.1016/S1359-6349(08)70548-2

CBE

Margolin S, Carlsson L, Hellström M, Karlsson P, Lidbrink E, Linderholm B, Lindman H, Malmström P, Sköld Pettersson D, Bergh J. 2008. A randomized feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer. European Journal of Cancer Supplements. 6(7):116-117. https://doi.org/10.1016/S1359-6349(08)70548-2

MLA

Margolin, S et al. "A randomized feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer". European Journal of Cancer Supplements. 2008, 6(7). 116-117. https://doi.org/10.1016/S1359-6349(08)70548-2

Vancouver

Margolin S, Carlsson L, Hellström M, Karlsson P, Lidbrink E, Linderholm B et al. A randomized feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer. European Journal of Cancer Supplements. 2008;6(7):116-117. https://doi.org/10.1016/S1359-6349(08)70548-2

Author

Margolin, S ; Carlsson, L ; Hellström, M ; Karlsson, P ; Lidbrink, E ; Linderholm, B ; Lindman, H ; Malmström, Per ; Sköld Pettersson, D ; Bergh, J. / A randomized feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer. I: European Journal of Cancer Supplements. 2008 ; Vol. 6, Nr. 7. s. 116-117.

RIS

TY - JOUR

T1 - A randomized feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer

AU - Margolin, S

AU - Carlsson, L

AU - Hellström, M

AU - Karlsson, P

AU - Lidbrink, E

AU - Linderholm, B

AU - Lindman, H

AU - Malmström, Per

AU - Sköld Pettersson, D

AU - Bergh, J

PY - 2008

Y1 - 2008

U2 - 10.1016/S1359-6349(08)70548-2

DO - 10.1016/S1359-6349(08)70548-2

M3 - Published meeting abstract

VL - 6

SP - 116

EP - 117

JO - European Journal of Cancer Supplements

JF - European Journal of Cancer Supplements

SN - 1359-6349

IS - 7

T2 - EBCC-6, European Breast Cancer Conference, 2008

Y2 - 14 April 2008 through 19 April 2008

ER -